These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 36574848)

  • 1. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
    Tauber J; Berdy GJ; Wirta DL; Krösser S; Vittitow JL;
    Ophthalmology; 2023 May; 130(5):516-524. PubMed ID: 36574848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study.
    Sheppard JD; Kurata F; Epitropoulos AT; Krösser S; Vittitow JL;
    Am J Ophthalmol; 2023 Aug; 252():265-274. PubMed ID: 36948372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease.
    Tauber J; Wirta DL; Sall K; Majmudar PA; Willen D; Krösser S;
    Cornea; 2021 Sep; 40(9):1132-1140. PubMed ID: 33369937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial.
    Tian L; Gao Z; Zhu L; Shi X; Zhao S; Gu H; Xu G; Wang L; Dai H; Zhang H; Jin X; Ma K; Xu Y; Ma L; Pei C; Ke B; Krösser S; Zhang Y; Jie Y
    JAMA Ophthalmol; 2023 Apr; 141(4):385-392. PubMed ID: 36929413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study.
    Protzko EE; Segal BA; Korenfeld MS; Krösser S; Vittitow JL
    Cornea; 2024 Sep; 43(9):1100-1107. PubMed ID: 37921522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease.
    Steven P; Augustin AJ; Geerling G; Kaercher T; Kretz F; Kunert K; Menzel-Severing J; Schrage N; Schrems W; Krösser S; Beckert M; Messmer EM
    J Ocul Pharmacol Ther; 2017 Nov; 33(9):678-685. PubMed ID: 28922088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease.
    Zhuang-Yan A; Syed YY
    Drugs; 2024 Apr; 84(4):441-448. PubMed ID: 38554243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction.
    Cote S; Zhang AC; Ahmadzai V; Maleken A; Li C; Oppedisano J; Nair K; Busija L; Downie LE
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013559. PubMed ID: 32182637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
    Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
    JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study.
    Toyos R; Desai NR; Toyos M; Dell SJ
    PLoS One; 2022; 17(6):e0270268. PubMed ID: 35737696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of 0.05% cyclosporine A combined with vitamin A palmitate in the treatment of meibomian gland dysfunction-related dry eye].
    Hao YR; Li SY; Bao JY; Wang JY; Li A; Tian L; Jie Y
    Zhonghua Yan Ke Za Zhi; 2024 Feb; 60(2):127-136. PubMed ID: 38296318
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of intense pulsed light therapy in the treatment of Meibomian gland dysfunction-related severe dry eye].
    Egri S; Van Hollebecke I; Guindolet D; Manenti C; Rougier H; Gabison É; Cochereau I; Doan S
    J Fr Ophtalmol; 2021 Feb; 44(2):169-175. PubMed ID: 33358077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Perfluorohexyloctane in Evaporative Dry Eye Disease Associated With Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Guedes J; Hespanhol LC; Freitas MAA; Balieiro CCA; Souza MEC; Faneli AC; Melo HSS; Mora-Paez DJ; Fontes BM
    Cureus; 2024 Aug; 16(8):e67920. PubMed ID: 39206330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
    Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
    JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Topical Vitamin D in the Management of Dry Eye Disease Associated With Meibomian Gland Dysfunction: A Placebo-Controlled Double-Blind Randomized Controlled Trial.
    Hassanpour K; Langari F; Akbarzadeh AR; Kanavi MR; Barani M; Kheiri B; Karimian F; Ahmadieh H; Sadoughi MM
    Cornea; 2024 May; 43(5):552-563. PubMed ID: 37815305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation into the effects of ocular nebulization combined with meibomian gland massage on ocular surface status and corneal higher-order aberrations for the treatment of meibomian gland dysfunction.
    Lin F; Mao X; Ma L; Liu H
    Acta Ophthalmol; 2022 May; 100(3):e681-e693. PubMed ID: 34331838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial.
    Peng R; Jie Y; Long Q; Gong L; Zhu L; Zhong X; Zhao S; Yan X; Gu H; Wu H; Li G; Zhang K; Krösser S; Xu R; Hong J
    JAMA Ophthalmol; 2024 Apr; 142(4):337-343. PubMed ID: 38451509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
    Peng WY; Chen RX; Dai H; Zhu L; Li Y; Gao ZQ; Li XY; Zhou SY
    Clin Ther; 2021 Mar; 43(3):613-628. PubMed ID: 33546885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.